Kazia Therapeutics (KZIA) News Today $0.88 +0.00 (+0.11%) Closing price 02/21/2025 03:57 PM EasternExtended Trading$0.87 -0.01 (-1.14%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Kazia Therapeutics announces research grant awarded from MJFFFebruary 20 at 10:49 AM | markets.businessinsider.comMaxim Group Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt () (KZIA) with Buy RecommendationFebruary 8, 2025 | msn.comMaxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study dataFebruary 6, 2025 | markets.businessinsider.comKazia Therapeutics initiated with a Buy at MaximFebruary 6, 2025 | markets.businessinsider.comIs Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?January 31, 2025 | msn.comKazia Therapeutics launches trial of paxalisib/immunotherapy combinationJanuary 30, 2025 | markets.businessinsider.comKazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerJanuary 30, 2025 | prnewswire.comWhy Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?January 27, 2025 | msn.comKazia Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingJanuary 14, 2025 | prnewswire.comKazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offeringJanuary 10, 2025 | markets.businessinsider.comKazia Therapeutics Announces Pricing Of $2 Mln Registered Direct Offering At $1.50/ADSJanuary 10, 2025 | markets.businessinsider.comKazia Therapeutics Announces $2.0 Million Registered Direct OfferingJanuary 10, 2025 | prnewswire.comKazia Therapeutics Limited: Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDADecember 31, 2024 | finanznachrichten.deKazia Therapeutics Shares Fall After FDA Declines Accelerated Drug ApprovalDecember 31, 2024 | marketwatch.comKazia says glioblastoma trial data won’t support FDA accelerated nod for lead drugDecember 31, 2024 | msn.comKazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDADecember 31, 2024 | prnewswire.comKazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer TreatmentDecember 12, 2024 | markets.businessinsider.comKazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumDecember 11, 2024 | prnewswire.comKazia Therapeutics Secures Nasdaq ComplianceNovember 13, 2024 | markets.businessinsider.comKazia Therapeutics Advances Paxalisib with FDA MeetingNovember 4, 2024 | markets.businessinsider.comKazia Therapeutics announces granting of Type C meeting with FDANovember 4, 2024 | markets.businessinsider.comKazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma MultiformeNovember 4, 2024 | prnewswire.comKazia Therapeutics trading halted, news pendingOctober 26, 2024 | markets.businessinsider.comKazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq ListingOctober 16, 2024 | finance.yahoo.comKazia Therapeutics (NASDAQ:KZIA) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comKazia Announces Positive Phase 1 Data For Concurrent Paxalisib, Radiation Therapy In Brain TumorOctober 3, 2024 | markets.businessinsider.comKazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual MeetingOctober 2, 2024 | prnewswire.comKazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumSeptember 23, 2024 | prnewswire.comKAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERSeptember 12, 2024 | prnewswire.comKazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?July 31, 2024 | investorplace.comBiotech Stock Laboratory: Try a Small Experiment With Kazia TherapeuticsJuly 25, 2024 | investorplace.comFrom Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode HigherJuly 12, 2024 | investorplace.comKZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% GainsJuly 11, 2024 | investorplace.comWhy Is Kazia Therapeutics (KZIA) Stock Up 300% Today?July 10, 2024 | investorplace.comKazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaJuly 10, 2024 | prnewswire.comKAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERJune 27, 2024 | prnewswire.comKazia Therapeutics Limited: Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementMay 24, 2024 | finanznachrichten.deKazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementMay 23, 2024 | prnewswire.comKAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSMay 1, 2024 | prnewswire.comKazia Therapeutics Ltd ADR KZIAMarch 20, 2024 | morningstar.comKZIA Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comKazia announces presentation of new data at AACR Annual MeetingMarch 13, 2024 | prnewswire.comWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?February 21, 2024 | msn.comKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | finanznachrichten.deKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | finance.yahoo.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | prnewswire.comKazia Therapeutics LimitedFebruary 19, 2024 | thestreet.comKazia Therapeutics Ltd. ADRFebruary 14, 2024 | wsj.comViking Therapeutics, Inc. Common Stock (VKTX)February 13, 2024 | nasdaq.comKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSJanuary 18, 2024 | finance.yahoo.com Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address KZIA Media Mentions By Week KZIA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KZIA News Sentiment▼1.270.60▲Average Medical News Sentiment KZIA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KZIA Articles This Week▼10▲KZIA Articles Average Week Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MEIP News QNTM News AFMD News SLGL News SPRB News SYBX News GOVX News NRSN News BMRA News EGRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KZIA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
